Oncology Dose optimisation in oncology: Insights from AACR 2026 and i... Five years after its launch, the FDA’s Project Optimus remained a key theme in discussions at AACR 2026.
Oncology From promise to practice: What must happen next for genetic ... The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Oncology From preclinical toxicology to clinical safety: The path for... Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
Oncology Advancing the case for cell and gene therapies After the Advanced Therapies Congress, Europe, pharmaphorum spoke with Resolution Therapeutics' Lara Campana and Vianautis' Dr Sam Barker.
Oncology Radiopharmaceutical development is accelerating. Preclinical... Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
News Capricor sues partner Nippon Shinyaku in DMD therapy spat Capricor has filed a lawsuit seeking to split from its commercial partner for Duchenne muscular dystrophy therapy, deramiocel, in the US.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
